Alexandria Real Estate: An 8% Cap Rate For Labs Leased To Lilly And Bristol Myers

Alexandria Real Estate Equities is described as undervalued, with estimated fair value of $60 versus a $40.86 closing price. 2027 is expected to be the trough year, with FFO per share estimated at around $5.00 and occupancy pressured by major lease expirations. The shares trade at a significant discount to peers despite higher occupancy and a blue-chip tenant base, while the market is pricing in further downside risk.

Analysis

The valuation case is asymmetric only if the 2027 trough is already substantially reflected in rents and asset values. High occupancy and blue-chip tenants may cushion cash flow, but they do not eliminate rollover risk: large expirations can shift bargaining power to tenants, raising concessions, tenant-improvement spending and downtime before reported occupancy weakens. A soft leasing market could therefore pressure cash NOI and appraisals with a lag.

The key read-through is biotech tenant funding and lab-space utilization, not occupancy alone. Weak venture funding or subdued pharma expansion would extend the time needed to re-lease space and could force more incentives; that would also weigh on competing life-science landlords. Conversely, limited new supply and improving tenant demand would make the trough narrative more credible. The $60 fair-value estimate is an analyst assumption, not a near-term catalyst; without its cap-rate, rent and leasing inputs, the apparent discount should not be treated as a margin of safety.

Near term, watch leasing spreads, renewal rates, concessions, tenant-improvement outlays and management’s 2027 FFO guidance. Over 6–18 months, successful absorption of expirations could support a relative re-rating; persistent negative leasing economics or higher property yields would undermine NAV even if occupancy remains respectable. A relative-value long ARE versus a diversified REIT basket is more defensible than an outright valuation bet, but the life-science exposure means the hedge will be imperfect.

Key Decisions for Investors

• Do not anchor on the $60 estimate alone. Before initiating, verify the expiration schedule by year, leasing spreads, renewal/retention rates, concessions and tenant-improvement spending; these determine whether the projected trough is an earnings floor or merely a forecast.
• Watch-list a staged long ARE position for investors seeking life-science real-estate exposure; prefer entries after leasing or guidance evidence confirms stabilization rather than buying solely on the stated discount. Size for further downside if rollover costs rise.
• If taking a relative-value position, consider long ARE against a diversified REIT basket rather than treating another landlord as a clean hedge. Reassess if ARE’s leasing metrics deteriorate relative to the sector; portfolio mix can make peer pairs misleading.
• Falsify the recovery thesis if management lowers 2027 FFO expectations, leasing spreads or retention weaken materially, concessions and tenant-improvement costs rise, or capitalization rates move higher enough to erode private-market values. Improving leasing economics and stable guidance would support the thesis.